Abstract 672P
Background
Open sharing of synthetic trial data could facilitate secondary analyses and synthetic control arm development.
Methods
This study included 128 experimental vs. control treatments for solid tumors from 115 phase 3 randomized clinical trials (RCTs) published in 7 high-impact journals in 2023. Original individual patient data were reconstructed from the published Kaplan-Meier curves of overall survival (OS) in the intention-to-treat population. Either both arms (fully synthetic; retaining original sample size) or only the control arm (partially synthetic; retaining original control arm size) were synthesized using statistical models (Weibull and Synthpop) and a deep generative model (SurvivalGAN). Original and synthetic RCTs were compared through the probability overlap (0: none, 1: perfect) of the 95% confidence intervals (CIs) for the hazard ratio (HR), and the true (TPR) and false positive rate (FPR) with respect to the direction of the HR and its statistical significance on the 0.05 level.
Results
The median sample size was 571 (range 82-5637) and the median HR for OS was 0.80 (range 0.39-1.14) in the original (reconstructed) RCTs. Fifty-six (43.8%) were statistically significant, all of which showing superiority of the experimental treatment. The results presented in the table indicate that the use of synthetic arms may introduce bias due to generative model misspecification (in particular for fully synthetic RCTs created by Weibull) and additional variability inherent to the data generating process (more pronounced in fully vs. partially synthetic RCTs and in deep generative vs. statistical models), leading to insufficient CI overlap for the HR and thereby impacting statistical inference. TPR ranges from 2.6% to 80.4% and 90.9% to 98.2% in fully and partially synthetic RCTs, while FPR ranges from 25.0% to 46.4% and 27.8% to 44.4%, respectively. Table: 672P
Results of the synthetic RCTs
Approach | Model | Difference in log HR: mean (sd) | 95% CI overlap: mean (sd) | TPR: % | FPR: % |
Full | Weibull | 0.33 (0.43) | 0.43 (0.39) | 2.6 | 29.5 |
Full | Synthpop | 0.01 (0.20) | 0.84 (0.20) | 80.4 | 25.0 |
Full | SurvivalGAN | -0.01 (0.73) | 0.46 (0.35) | 66.0 | 46.4 |
Partial | Weibull | -0.11 (0.15) | 0.81 (0.23) | 90.9 | 32.4 |
Partial | Synthpop | -0.10 (0.25) | 0.85 (0.26) | 96.4 | 27.8 |
Partial | SurvivalGAN | -0.14 (0.23) | 0.71 (0.31) | 98.2 | 44.4 |
Conclusions
Naive inference from RCTs with synthetic arms may lead to overly optimistic or even wrong conclusions.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Ghent University.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
651P - Phase I study of XNW27011, a novel claudin 18.2 ADC, in patients with locally advanced and/or metastatic solid tumors
Presenter: Jinming Yu
Session: Poster session 01
652P - BT8009 monotherapy in enfortumab vedotin (EV)-naïve patients (pts) with metastatic urothelial carcinoma (mUC): Updated results of Duravelo-1
Presenter: Oscar Reig Torras
Session: Poster session 01
653P - A phase I dose escalation study of EBC-129, a first-in class, anti N-glycosylated CEACAM5 & CEACAM6 antibody-drug conjugate (ADC) in patients with solid tumors
Presenter: Matthew Chau Hsien Ng
Session: Poster session 01
654P - Peripheral neuropathy (PN) following treatment (tx) with bicycle toxin conjugates (BTCs) BT8009 or BT5528 monotherapy in patients (pts) with advanced solid tumors
Presenter: Bernard Doger de Spéville
Session: Poster session 01
655P - Toxicity and efficacy of antibody drug conjugates (ADC) in advanced solid tumors: A pooled analysis of Sarah Cannon UK
Presenter: Rachel Woodford
Session: Poster session 01
656P - Phase I/Ib open-label study of an HER2-targeted T cell engager (TCE)‒SAR443216 in patients (pts) with advanced solid tumors: Intravenous (IV) dose-escalation results
Presenter: Victor Moreno Garcia
Session: Poster session 01
657P - Prospective validation of the T cell engager (TCE) score in patients treated with bispecific CD3 TCE antibodies in phase I clinical trials
Presenter: Noé Herbel
Session: Poster session 01
658P - First-in-human phase I trial of oncolytic herpes simplex virus ONCR-177 alone or in combination with pembrolizumab in advanced solid tumors
Presenter: Cátia Fava Gaspar
Session: Poster session 01
659P - Combination treatment with TTX-030, a first-in-class anti-CD39 antibody, in patients with advanced pancreatic cancer
Presenter: Zev Wainberg
Session: Poster session 01
660P - Atezolizumab plus UCPvax telomerase CD4 TH1-inducer cancer vaccine for the treatment of chemorefractory HPV+ cancers: Safety and efficacy results of the VolATIL phase II study
Presenter: Laura Mansi
Session: Poster session 01